“Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s144. doi:10.25251/skin.7.supp.144.